Abbott Laboratories (ABT) - Medical Equipment - Deals and Alliances Profile

Abbott Laboratories (ABT) - Medical Equipment - Deals and Alliances Profile


  • Products Id :- GDME1255D
  • |
  • Pages: 211
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Abbott Laboratories (Abbott) develops, manufactures, and sells a diversified range of healthcare products including drugs, diagnostics, branded generics, and vascular and nutritional products. The company's products comprise specialized medicines; medical diagnostic instruments and tests; minimally invasive surgical devices; nutritional supplements for infants, children and adults; and products for veterinary care. It has research and development, manufacturing and administrative facilities across the world. The company markets its products in North America, Latin America, the Caribbean, the Middle East, Europe, Asia-Pacific and Africa. Abbott is headquartered in Abbott Park, Illinois, the US.

Abbott Laboratories (ABT)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 7

List of Figures 9

Abbott Laboratories, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Abbott Laboratories, Medical Equipment Deals By Type, 2012 to YTD 2018 11

Abbott Laboratories, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Abbott Laboratories, Medical Equipment, Deals By Market, 2012 to YTD 2018 13

Abbott Laboratories, Medical Equipment, Deals Summary, 2012 to YTD 2018 14

Abbott Laboratories, Medical Equipment, Deal Details 20

Asset Purchase 20

Abbott Labs Plans to Acquire Medical Optics and Other Products 20

Thoratec Acquires DuraHeart II Ventricular Assist System From Terumo For USD 56.5 Million 21

Venture Financing 23

Bigfoot Biomedical Raises USD55 Million in Final Tranche of Series B financing 23

Kalila Medical Raises Funds Through Venture Financing 25

Tendyne Raises USD 25 Million In Series C Financing 26

Tendyne Raises USD 1 Million In Venture Financing 27

Spinal Modulation Raises USD 40 Million In Venture Financing 28

Tendyne Raises Additional USD 2.6 Million In Venture Financing 29

Nanostim Raises USD 9.5 Million In Series C Financing 30

Topera Raises USD 25 Million In Series C Financing 31

Spinal Modulation Raises USD 2 Million In Venture Financing 32

OptiMedica Raises USD 35 Million In Venture Financing 33

Nanostim Raises USD 10 Million In Venture Financing 35

Topera Raises USD 4 Million In Venture Financing 36

Tendyne Raises USD 9 Million In Venture Financing 37

Nanostim Raises USD 10 Million In Venture Financing 38

Topera Raises USD 2.8 Million In Venture Financing 39

IDev Technologies Raises USD 0.83 Million In Venture Financing 40

Private Equity 41

Pharos Capital Group Acquires Majority Stake in TechLab 41

Exponent Private Equity Acquires BBI Diagnostics from Alere for USD162 Million 42

Partnerships 43

Abbott Lab Enters into Licensing Agreement with SurModics 43

Abbott Labs Enters into Licensing Agreement with Beijing Strong Biotechnologies 44

Axis-Shield Enters into Licensing Agreement with Hangzhou Joinstar Biomedical 45

Insulet Extends Licensing Agreement with Abbott Diabetes Care 46

BioPorto Diagnostics Enters Into Licensing Agreement With Abbott Labs 47

Axis-Shield Diagnostic Enters into Licensing Agreement with Siemens Healthcare Diagnostics 48

Robert Bosch Healthcare Systems Enters Into Licensing Agreement With Abbott Diabetes Care 49

Abbott Enters Into Licensing Agreement With Stanford University For Prostate Cancer Biomarkers 50

Insulet Amends Licensing Agreement With Abbott Diabetes 51

Roxwood Medical Enters into Distribution Agreement with Abbott Vascular 52

Abbott Labs and Bigfoot Biomedical Enter into Agreement 53

Akers Biosciences Enters into Distribution Agreement with First Check Diagnostics 54

Celgene and Agios Pharma Enter into Agreement with Abbott Labs 55

Diasend Partners with Abbott Labs 56

MATTER Enters into Agreement with Abbott 57

Abbott Enters into Agreement with GE Healthcare 58

Abbott Labs Enters into Agreement with Sekisui Diagnostics for Coagulation Testing 59

Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software 60

Abbott Labs Enters into Co-Development Agreement with US Department of Defense 61

Abbott Molecular Enters into Co-Development Agreement with Biocartis 62

Idera Pharma Enters Into Co-Development Agreement With Abbott Molecular For In Vitro Companion Diagnostic Test 63

Abbott Enters Into Distribution Agreement With R-Pharm For Diabetes Care Products 64

St. Jude Medical Enters Into Distribution Agreement With Spinal Modulation For Axium Neurostimulator System 65

Epizyme Enters Into Co-Development Agreement With Abbott Labs 66

BioGenex Labs Enters Into Co-Marketing Agreement With Abbott Molecular 67

Cellavision Enters Into Distribution Agreement With Abbott 68

Abbott Molecular Enters Into Agreement With Janssen Biotech And Pharmacyclics For Leukemia Test 69

BioView Enters Into Agreement With Abbott To Develop Automated Cancer Screening System 70

Abaxis Enters Into Distribution Agreement With Abbott Point of Care For Piccolo Blood Chemistry System 71

Alere Enters Into Co-Development Agreement With AT&T 72

Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 73

Abbott Vascular Enters Into Co-Marketing Agreement With St. Jude Medical 74

Abbott Enters Into Co-Development Agreement With Genetics Lab For Molecular Assay Development 75

Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay For Sepsis 76

Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 77

Equity Offering 78

Abbott Labs Plans to Raise USD3 Billion in Public Offering of Shares 78

Debt Offering 79

Abbott Labs Raises USD1.33 Billion in Public Offering of 1.5% Bonds Due 2026 79

Abbott Labs Raises USD1.33 Billion in Public Offering of 0.875% Bonds Due 2023 80

Abbott Labs Raises USD1.33 Billion in Public Offering of Bonds Due 2020 81

Abbott Labs Raises USD3 Billion in Public Offering of 3.75% Notes due 2026 82

Abbott Labs Raises USD1.5 Billion in Public Offering of 3.4% Notes Due 2023 84

Abbott Labs Raises USD1.65 Billion in Public Offering of 4.75% Notes due 2036 86

Abbott Labs Raises USD2.85 Billion in Public Offering of 2.9% Notes due 2021 88

Abbott Labs Raises USD2.85 Billion in Public Offering of 2.35% Notes due 2019 90

Abbott Labs Raises USD3.25 Billion in Public Offering of 4.9% Notes due 2046 92

Alere Raises USD425 Million in Private Placement of 6.37% Notes Due 2023 94

Abbott Labs Raises USD750 Million in Public Offering of 2.55% Notes Due 2022 95

Abbott Labs Raises USD1 Billion in Public Offering of 2.55% Notes Due 2025 96

Abbott Labs Raises USD2.5 Billion in Public Offering of 2% Notes Due 2020 97

Alere Completes Private Placement Of Notes Due 2020 For USD 425 Million 98

St. Jude Medical Completes Public Offering Of Notes Due 2043 For USD 700 Million 99

St. Jude Medical Completes Public Offering Of Notes Due 2023 For USD 900 Million 101

Alere Completes Private Placement Of Notes Due 2018 For USD 450 Million 103

Abbott Completes Private Placement Of Notes Due 2018 For USD 1 Billion 104

Abbott Completes Private Placement Of Notes Due 2022 For USD 3.1 Billion 105

Abbott Completes Private Placement Of Notes Due 2042 For USD 2.6 Billion 106

Abbott Completes Private Placement Of Notes Due 2015 For USD 3.5 Billion 107

Abbott Completes Private Placement Of Notes Due 2017 For USD 4 Billion 108

Abbott Completes Private Placement Of Notes Due 2015 For USD 500 Million 109

Asset Transactions 110

Quidel Acquires Triage and BNP Business from Alere 110

Terumo Acquires Portion of Vascular Closure Portfolio and Other Assets from St. Jude Medical and Abbott Labs for USD1.12 Billion 112

QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 114

Coppersmith Capital Management Reportedly Wants Alere To Explore Sale Of Its Drug Testing And Toxicology Businesses For Up To USD 5 Billion 115

Vascular Solutions Acquires Venture Catheter From St. Jude Medical For USD 3 Million 116

Acquisition 117

Siemens Healthineers Acquires Epocal from Alere 117

Abbott Labs Acquires Alere 118

Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 120

Abbott Labs Acquires St. Jude Medical for up to USD23.6 Billion 121

Abbott Labs Acquires Kalila Medical 123

St. Jude Medical Acquires Thoratec for USD3.3 Billion 124

Abbott Labs Acquires Remaining Stake in Tendyne for USD250 Million 126

Abbott Labs Enters into Option Agreement to Acquire Cephea Valve Technologies 127

Abbott Labs Acquires Omnilab 128

Alere Acquires US Diagnostics USD60 Million 129

St. Jude Medical Acquires Spinal Modulation 130

Abbott Labs Acquires Topera 131

Abbott Labs Receives Right to Acquire Advanced Cardiac Therapeutics 132

Ron Zwanziger Plans to Acquire Alere for USD3.82 Billion 133

Jude Medical Completes Acquisition of NeuroTherm for USD200 Million 134

St. Jude Medical Completes Acquisition of Remaining 81% Stake in CardioMEMS for USD450 Million 135

St. Jude Medical Completes Acquisition Of Nanostim For USD 123.5 Million 137

Abbott Laboratories Completes Acquisition Of IDev Technologies 139

Abbott Labs Completes Acquisition Of OptiMedica For Up To USD410 Million 141

St. Jude Medical Acquires Endosense, Developer Of Cardiovascular Devices 143

Alere Completes Acquisition Of Epocal For Up To USD 241 Million 145

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 147

Alere Acquires eScreen for USD296 Million 149

Arriva Medical Acquires AmMed Direct For USD 23 Million 151

STARLIMS Technologies Acquires Distribution Partners 152

Arriva Medical Acquires Direct Diabetic Source 153

Abbott Laboratories - Key Competitors 154

Abbott Laboratories - Key Employees 155

Abbott Laboratories - Locations And Subsidiaries 157

Head Office 157

Other Locations & Subsidiaries 157

Recent Developments 175

Financial Announcements 175

Jul 18, 2018: Abbott reports second-Quarter 2018 Results 175

Apr 18, 2018: Abbott Reports First-Quarter 2018 Results 178

Jan 24, 2018: Abbott Reports Fourth-Quarter 2017 Results 181

Oct 18, 2017: Abbott Reports Third-Quarter 2017 Results 184

Jul 20, 2017: Abbott Reports Second-Quarter 2017 Results 187

Apr 19, 2017: Abbott Reports First-Quarter 2017 Results 189

Corporate Communications 191

Aug 01, 2018: Global Healthcare Organizations join Abbott to launch the UNIVANTS of Healthcare Excellence Award 191

Sep 22, 2017: Abbott and the Abbott Fund Provide $2 Million in Additional Relief to Help Families Affected by Hurricane Maria and the Earthquake in Central Mexico 192

Sep 18, 2017: Abbott and the Abbott Fund Expand Support for Hurricane Relief With $1 Million to Help Families Affected by Hurricane Irma 193

Sep 07, 2017: Abbott Named Industry Leader for Responsible and Sustainable Business for Five Consecutive Years on the Dow Jones Sustainability Index 194

Aug 29, 2017: Abbott and the Abbott Fund Donate $1 Million to Support Hurricane Harvey Relief Efforts 195

Government and Public Interest 196

Sep 06, 2018: Eighth Annual MedtechVision Conference to Focus on The Impact of AI on Medicine 196

Jul 20, 2018: Rapid diagnostics deliver shared value 197

Apr 17, 2018: Battery Performance Alert and Cybersecurity Firmware Updates for Certain Abbott (formerly St. Jude Medical) Implantable Cardiac Devices: FDA Safety Communication 199

Product News 202

Apr 17, 2018: Abbott Releases Planned Updates for Implantable Cardiac Devices 202

Apr 11, 2018: Abbott Initiates Groundbreaking Study to Assess Superiority of High-Resolution Imaging Versus Standard-of-Care Angiography in Treating Coronary Artery Disease 203

Oct 30, 2017: Analysis of Landmark Study Showed Patients Treated for Left-Main Coronary Artery Disease With Xience Stent Felt Better Faster and Had Similar Long-Term Outcomes to Open-Heart Surgery 204

Aug 29, 2017: Abbott Issues New Updates for Implanted Cardiac Devices 205

Jul 25, 2017: Abbott Initiates Clinical Trial Of Three-Month Dual Antiplatelet Therapy Following Implantation With Xience Coronary Stent 207

Other Significant Developments 208

Jul 28, 2018: FIND announces new wave of activities to address the challenges threatening hepatitis C elimination through potential diagnostic technologies 208

Jun 19, 2018: ClearStar Expands Medical Testing with Abbott Laboratories Integration 209

Aug 15, 2017: North West London Pathology and Abbott Partner for Diagnostics Products and Services, Including Alinity, in Three NHS Trusts 210

Appendix 211

Methodology 211

About GlobalData 211

Contact Us 211

Disclaimer 211

List of Figures

Abbott Laboratories, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Abbott Laboratories, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Abbott Laboratories, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Abbott Laboratories, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Abbott Laboratories, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Abbott Laboratories, Medical Equipment, Deals by Type, 2012 to YTD 2018 11

Abbott Laboratories, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Abbott Laboratories, Medical Equipment, Deals by Market, 2012 to YTD 2018 13

List of Tables

Abbott Laboratories, Medical Equipment, Key Facts, 2017 2

Abbott Laboratories, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Abbott Laboratories, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Abbott Laboratories, Medical Equipment Deals By Type, 2012 to YTD 2018 11

Abbott Laboratories, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Abbott Laboratories, Deals By Market, 2012 to YTD 2018 13

Abbott Laboratories, Medical Equipment, Deals Summary, 2012 to YTD 2018 14

Abbott Labs Plans to Acquire Medical Optics and Other Products 20

Thoratec Acquires DuraHeart II Ventricular Assist System From Terumo For USD 56.5 Million 21

Bigfoot Biomedical Raises USD55 Million in Final Tranche of Series B financing 23

Kalila Medical Raises Funds Through Venture Financing 25

Tendyne Raises USD 25 Million In Series C Financing 26

Tendyne Raises USD 1 Million In Venture Financing 27

Spinal Modulation Raises USD 40 Million In Venture Financing 28

Tendyne Raises Additional USD 2.6 Million In Venture Financing 29

Nanostim Raises USD 9.5 Million In Series C Financing 30

Topera Raises USD 25 Million In Series C Financing 31

Spinal Modulation Raises USD 2 Million In Venture Financing 32

OptiMedica Raises USD 35 Million In Venture Financing 33

Nanostim Raises USD 10 Million In Venture Financing 35

Topera Raises USD 4 Million In Venture Financing 36

Tendyne Raises USD 9 Million In Venture Financing 37

Nanostim Raises USD 10 Million In Venture Financing 38

Topera Raises USD 2.8 Million In Venture Financing 39

IDev Technologies Raises USD 0.83 Million In Venture Financing 40

Pharos Capital Group Acquires Majority Stake in TechLab 41

Exponent Private Equity Acquires BBI Diagnostics from Alere for USD162 Million 42

Abbott Lab Enters into Licensing Agreement with SurModics 43

Abbott Labs Enters into Licensing Agreement with Beijing Strong Biotechnologies 44

Axis-Shield Enters into Licensing Agreement with Hangzhou Joinstar Biomedical 45

Insulet Extends Licensing Agreement with Abbott Diabetes Care 46

BioPorto Diagnostics Enters Into Licensing Agreement With Abbott Labs 47

Axis-Shield Diagnostic Enters into Licensing Agreement with Siemens Healthcare Diagnostics 48

Robert Bosch Healthcare Systems Enters Into Licensing Agreement With Abbott Diabetes Care 49

Abbott Enters Into Licensing Agreement With Stanford University For Prostate Cancer Biomarkers 50

Insulet Amends Licensing Agreement With Abbott Diabetes 51

Roxwood Medical Enters into Distribution Agreement with Abbott Vascular 52

Abbott Labs and Bigfoot Biomedical Enter into Agreement 53

Akers Biosciences Enters into Distribution Agreement with First Check Diagnostics 54

Celgene and Agios Pharma Enter into Agreement with Abbott Labs 55

Diasend Partners with Abbott Labs 56

MATTER Enters into Agreement with Abbott 57

Abbott Enters into Agreement with GE Healthcare 58

Abbott Labs Enters into Agreement with Sekisui Diagnostics for Coagulation Testing 59

Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software 60

Abbott Labs Enters into Co-Development Agreement with US Department of Defense 61

Abbott Molecular Enters into Co-Development Agreement with Biocartis 62

Idera Pharma Enters Into Co-Development Agreement With Abbott Molecular For In Vitro Companion Diagnostic Test 63

Abbott Enters Into Distribution Agreement With R-Pharm For Diabetes Care Products 64

St. Jude Medical Enters Into Distribution Agreement With Spinal Modulation For Axium Neurostimulator System 65

Epizyme Enters Into Co-Development Agreement With Abbott Labs 66

BioGenex Labs Enters Into Co-Marketing Agreement With Abbott Molecular 67

Cellavision Enters Into Distribution Agreement With Abbott 68

Abbott Molecular Enters Into Agreement With Janssen Biotech And Pharmacyclics For Leukemia Test 69

BioView Enters Into Agreement With Abbott To Develop Automated Cancer Screening System 70

Abaxis Enters Into Distribution Agreement With Abbott Point of Care For Piccolo Blood Chemistry System 71

Alere Enters Into Co-Development Agreement With AT&T 72

Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 73

Abbott Vascular Enters Into Co-Marketing Agreement With St. Jude Medical 74

Abbott Enters Into Co-Development Agreement With Genetics Lab For Molecular Assay Development 75

Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay For Sepsis 76

Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 77

Abbott Labs Plans to Raise USD3 Billion in Public Offering of Shares 78

Abbott Labs Raises USD1.33 Billion in Public Offering of 1.5% Bonds Due 2026 79

Abbott Labs Raises USD1.33 Billion in Public Offering of 0.875% Bonds Due 2023 80

Abbott Labs Raises USD1.33 Billion in Public Offering of Bonds Due 2020 81

Abbott Labs Raises USD3 Billion in Public Offering of 3.75% Notes due 2026 82

Abbott Labs Raises USD1.5 Billion in Public Offering of 3.4% Notes Due 2023 84

Abbott Labs Raises USD1.65 Billion in Public Offering of 4.75% Notes due 2036 86

Abbott Labs Raises USD2.85 Billion in Public Offering of 2.9% Notes due 2021 88

Abbott Labs Raises USD2.85 Billion in Public Offering of 2.35% Notes due 2019 90

Abbott Labs Raises USD3.25 Billion in Public Offering of 4.9% Notes due 2046 92

Alere Raises USD425 Million in Private Placement of 6.37% Notes Due 2023 94

Abbott Labs Raises USD750 Million in Public Offering of 2.55% Notes Due 2022 95

Abbott Labs Raises USD1 Billion in Public Offering of 2.55% Notes Due 2025 96

Abbott Labs Raises USD2.5 Billion in Public Offering of 2% Notes Due 2020 97

Alere Completes Private Placement Of Notes Due 2020 For USD 425 Million 98

St. Jude Medical Completes Public Offering Of Notes Due 2043 For USD 700 Million 99

St. Jude Medical Completes Public Offering Of Notes Due 2023 For USD 900 Million 101

Alere Completes Private Placement Of Notes Due 2018 For USD 450 Million 103

Abbott Completes Private Placement Of Notes Due 2018 For USD 1 Billion 104

Abbott Completes Private Placement Of Notes Due 2022 For USD 3.1 Billion 105

Abbott Completes Private Placement Of Notes Due 2042 For USD 2.6 Billion 106

Abbott Completes Private Placement Of Notes Due 2015 For USD 3.5 Billion 107

Abbott Completes Private Placement Of Notes Due 2017 For USD 4 Billion 108

Abbott Completes Private Placement Of Notes Due 2015 For USD 500 Million 109

Quidel Acquires Triage and BNP Business from Alere 110

Terumo Acquires Portion of Vascular Closure Portfolio and Other Assets from St. Jude Medical and Abbott Labs for USD1.12 Billion 112

QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 114

Coppersmith Capital Management Reportedly Wants Alere To Explore Sale Of Its Drug Testing And Toxicology Businesses For Up To USD 5 Billion 115

Vascular Solutions Acquires Venture Catheter From St. Jude Medical For USD 3 Million 116

Siemens Healthineers Acquires Epocal from Alere 117

Abbott Labs Acquires Alere 118

Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 120

Abbott Labs Acquires St. Jude Medical for up to USD23.6 Billion 121

Abbott Labs Acquires Kalila Medical 123

St. Jude Medical Acquires Thoratec for USD3.3 Billion 124

Abbott Labs Acquires Remaining Stake in Tendyne for USD250 Million 126

Abbott Labs Enters into Option Agreement to Acquire Cephea Valve Technologies 127

Abbott Labs Acquires Omnilab 128

Alere Acquires US Diagnostics USD60 Million 129

St. Jude Medical Acquires Spinal Modulation 130

Abbott Labs Acquires Topera 131

Abbott Labs Receives Right to Acquire Advanced Cardiac Therapeutics 132

Ron Zwanziger Plans to Acquire Alere for USD3.82 Billion 133

Jude Medical Completes Acquisition of NeuroTherm for USD200 Million 134

St. Jude Medical Completes Acquisition of Remaining 81% Stake in CardioMEMS for USD450 Million 135

St. Jude Medical Completes Acquisition Of Nanostim For USD 123.5 Million 137

Abbott Laboratories Completes Acquisition Of IDev Technologies 139

Abbott Labs Completes Acquisition Of OptiMedica For Up To USD410 Million 141

St. Jude Medical Acquires Endosense, Developer Of Cardiovascular Devices 143

Alere Completes Acquisition Of Epocal For Up To USD 241 Million 145

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 147

Alere Acquires eScreen for USD296 Million 149

Arriva Medical Acquires AmMed Direct For USD 23 Million 151

STARLIMS Technologies Acquires Distribution Partners 152

Arriva Medical Acquires Direct Diabetic Source 153

Abbott Laboratories, Key Competitors 154

Abbott Laboratories, Key Employees 155

Abbott Laboratories, Other Locations 157

Abbott Laboratories, Subsidiaries 157

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Abbott Laboratories, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17835
Site License
USD 500 INR 35670
Corporate User License
USD 750 INR 53505

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com